Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$517.3MCash, Jun 2026
69moCash Runway (est.)
Follow AKTS by emailGet an email when AKTS pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about AKTS, unsubscribe in one click. Privacy
📣 What AKTS Says Is Next
second half of 2026 · “AKY-2519: o Expect to commence Phase 1b BActinium-2 basket trial in lung and other B7-H3 expressing solid tumor cancers in the second half of 2026. o Expect preliminary data from Phase 1b mCRPC clinical trial in 2027.”
Company press release, Aug 13, 2026 · SEC filing
first quarter of 2027 · “AKY-1189: o Expect preliminary data from the ongoing Phase 1b NECTINIUM-2 clinical trial in the first quarter of 2027.”
Company press release, Aug 13, 2026 · SEC filing
second half of 2026 · “Plan to initiate a Phase 1b basket trial in patients with lung, colorectal, and other B7-H3 expressing solid tumors in the second half of 2026.”
Company press release, May 11, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
AKTS reported $517.3M in cash and short-term investments (as of Jun 30, 2026) and used about $22.6M/quarter in operations, an estimated runway of 68.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:0 · Low
Cash runway 69 months
S-1 registration (Dec 2025) +8
Company says cash lasts into 2029 -15Based upon our current operating plans, we believe our existing cash, cash equivalents, and marketable securities will be sufficient to fund our operations into 2029.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Jan 9, 2026 · Underwritten offering, $318M · 424B4
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AKTS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.